Section 232 Pharma and Polysilicon Comment Period

Section 232 tariffs on specialty pharmaceuticals and polysilicon now carry additional procedural demands for affected importers. A 60-day comment period gives companies an opportunity to address the burden and clarity of two emergency information collections, but it does not change the underlying tariff rates, eligibility standards, or filing deadlines.

What the BIS Comment Period Covers

Two Collections With Different Commercial Objectives

The Bureau of Industry and Security published the two 60-day Paperwork Reduction Act notices on November 6, 2026. Comments are due on or before January 5, 2027. Although the notices were issued together, the underlying collections serve different purposes and should not be treated as a single compliance process.

The pharmaceutical collection, identified by OMB Control Number 0694-0150, supports Urgent Health Need Requests involving certain specialty pharmaceuticals and pharmaceutical ingredients. Eligible parties may seek a zero percent Section 232 tariff rate by demonstrating that a product meets the applicable urgent health need criteria.

The polysilicon collection, identified by OMB Control Number 0694-0149, supports waiver requests from importers of record seeking relief from specified import qualification or stockpiling restrictions. These waivers relate to the Section 232 measures governing certain polysilicon products, including minimum import prices and tariffs.

What Companies May Address in Comments

Comments should generally focus on whether the requested information is necessary, whether estimated burden hours are realistic, whether instructions are sufficiently clear, and whether the process could be improved without compromising program objectives. Companies that have prepared or filed requests are often best positioned to identify duplicative fields, unclear terminology, or data that is difficult to obtain within the expected timeframe.

Comments concerning the pharmaceutical collection should cite OMB Control Number 0694-0150. Polysilicon comments should cite OMB Control Number 0694-0149. The public comment process is separate from submitting an individual urgent health need request or polysilicon waiver application.

Pharmaceutical Urgent Health Need Requests

Building a Product-Specific Administrative Record

The pharmaceutical collection supports the temporary framework established under Proclamation 11020 and the related September 23, 2026 temporary final rule. Certain designated specialty pharmaceuticals may qualify for a zero percent rate when they originate from a jurisdiction covered by a current or forthcoming trade and security framework agreement. A product may also qualify if it satisfies the urgent health need standard.

An Urgent Health Need Request generally requires organizational information and a precise description of the product. Relevant data includes the HTSUS classification, country of origin, importer of record, and sufficient product information to connect the request to the merchandise that will enter the United States.

The substantive rationale is equally important. Applicants should typically explain the disease or condition treated, the availability and suitability of alternative therapies, and the estimated number of domestic patients affected. The record should connect the product's clinical role to the requested tariff treatment rather than relying on broad statements about healthcare access or commercial importance.

Operational Implications for Importers and Brokers

The collection is voluntary in the sense that an importer is not required to request special treatment. Once a company elects to seek the zero percent rate, however, the quality and completeness of the submission become central to the determination.

BIS estimates 250 respondents at approximately 8 hours per response, for a total estimated burden of 2,000 hours. Actual preparation time may be higher when tariff classification, origin, medical evidence, patient estimates, and internal approvals are maintained by different departments.

Requests continue on a rolling, one-product-per-email basis. Importers should preserve the complete submission, attachments, correspondence, and final determination. Brokers should also obtain clear instructions before applying any special tariff treatment to an entry.

Polysilicon Waiver Requests

Information Expected From Importers of Record

The polysilicon collection supports waiver applications related to the temporary final rule issued under Proclamation 11052. The underlying Section 232 measures include minimum import prices and tariffs on specified polysilicon products, along with qualification and stockpiling controls that may affect import activity.

An importer of record seeking a waiver generally must explain how the imported polysilicon will be used, the anticipated types and volumes of imports, the ownership or control structure associated with the transaction, and the legitimate business purpose for the requested relief. Commerce may also require other supporting information necessary to evaluate whether the facts satisfy the relevant waiver criteria.

The collection is voluntary because an importer may choose not to seek a waiver. It is not optional for a company that needs an affirmative waiver determination to proceed under the requested treatment. A concise application can still require substantial coordination among procurement, trade compliance, legal, finance, and operations teams.

Timing and Recordkeeping Risks

BIS estimates 165 applications at approximately 2 hours each, for a total of 330 burden hours. That estimate may not capture the time required to validate projected volumes, document end uses, confirm corporate relationships, and reconcile the application with purchase contracts or inventory plans.

The applicable waiver window closes December 3, 2026, which is earlier than the January 5, 2027 deadline for comments on the information collection. Importers should not confuse the opportunity to comment with an extension of the waiver filing period.

Every submitted version should be retained with its supporting calculations and correspondence. If anticipated import types, volumes, or uses change, the importer should assess whether the existing record remains accurate and whether supplemental communication is appropriate.

Compliance and Duty Drawback Considerations

Separate Administrative and Entry Processes

The comment notices do not modify Section 232 tariff rates, expand product eligibility, or automatically authorize special treatment at entry. They concern the information collected by Commerce. Importers, customs brokers, and trade counsel must continue to manage the underlying tariff requirements independently.

A defensible process begins with product classification and scope analysis. Teams should confirm the HTSUS provision, country of origin, importer of record, applicable proclamation, effective date, and any product-specific determination. The approved request or waiver should then be linked to the relevant entry records and broker instructions.

Importers should also establish controls that prevent a pending application from being treated as an approval. Unless the governing framework provides otherwise, a request under review generally does not establish eligibility for a lower rate or waiver. Entry instructions should clearly distinguish approved products from products that remain subject to the default treatment.

Evaluating Section 232 Duty Drawback

The new information collections do not change drawback eligibility. Section 232 duty drawback must be evaluated under the language of the governing proclamation, implementing instructions, and the facts of the import and export transactions.

Importers should not assume that every additional duty is recoverable merely because qualifying merchandise is later exported or destroyed. Some trade measures restrict drawback, while others may permit it under specified conditions. The analysis should address the particular duty assessed, the applicable proclamation language, the entry data, the chosen drawback provision, and the evidence connecting imports to exports or destruction.

Brokers evaluating potential claims should preserve entry summaries, commercial invoices, duty calculations, product identifiers, inventory records, export documentation, and any Commerce determination. Pharmaceutical and polysilicon importers should also separate ordinary customs duties from additional Section 232 amounts so that potential recovery can be assessed accurately.

Frequently Asked Questions

When Are Comments on the Collections Due?

Comments on both emergency information collections are due on or before January 5, 2027. Pharmaceutical comments should identify OMB Control Number 0694-0150, while polysilicon comments should identify OMB Control Number 0694-0149. Companies may address estimated burden, necessity, clarity, and potential improvements to the collection process.

Do the Notices Change Section 232 Tariff Rates?

No. The notices concern information collection requirements and public comments under the Paperwork Reduction Act. They do not change tariff rates, create new exemptions, broaden eligibility, or extend separate filing windows. Importers must continue to follow the applicable proclamation, temporary final rule, and operational instructions.

Is an Urgent Health Need Request Mandatory?

The pharmaceutical collection is voluntary. A company generally submits an Urgent Health Need Request only when it seeks the associated zero percent treatment based on urgent health need criteria. Once submitted, the request should contain complete and accurate product, origin, importer, therapeutic, alternative treatment, and patient information.

Is the Polysilicon Comment Deadline the Same as the Waiver Deadline?

No. The comment period ends January 5, 2027, but the polysilicon waiver window closes December 3, 2026. Commenting on the collection does not preserve waiver rights or extend the application period. Importers needing a waiver should manage the earlier operational deadline separately.

Can Section 232 Pharmaceutical or Polysilicon Duties Be Claimed Through Drawback?

Possibly, but eligibility depends on the governing measure and the transaction facts. The information collection notices do not authorize or prohibit drawback. Importers and brokers should review the applicable proclamation and implementation requirements before including any Section 232 duty in a drawback claim.

How Stable Software Can Help

A Broker-Controlled Drawback Model

Section 232 measures can create significant duty exposure, but recovery opportunities require careful eligibility analysis and reliable supporting records. DrawbackAI is flat-license duty drawback software that U.S. customs brokers can white-label for importer clients. Brokers file under their own filer codes and retain control of the client relationship and claim process.

Stable Software charges a flat software license and never takes a percentage of the refund. For brokers evaluating drawback opportunities involving pharmaceutical, polysilicon, or other imports, this structure supports a predictable software cost without tying fees to the value of client recoveries.

Resources